Biogen
Biogen Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of neurological disease research since its founding in 1978. With a strong presence in North America, Europe, and Asia, Biogen focuses on developing innovative therapies for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease. Renowned for its pioneering work in monoclonal antibodies, Biogen's core products include the multiple sclerosis treatments Tecfidera and Ocrevus, which are distinguished by their efficacy and safety profiles. The company has achieved significant milestones, including the first FDA approval of a treatment for spinal muscular atrophy in 2016. As a key player in the biotechnology industry, Biogen continues to push the boundaries of science, solidifying its market position through a commitment to research and development, and a robust pipeline of potential therapies.
DitchCarbon Score
How does Biogen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biogen's score of 97 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biogen's reported carbon emissions
In 2024, Biogen reported total carbon emissions of approximately 324,178,000 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 267,059,000 kg CO2e. Scope 1 emissions were approximately 56,611,000 kg CO2e, while Scope 2 emissions totalled about 50,700 kg CO2e (market-based). Biogen has set ambitious climate commitments, aiming to achieve net-zero greenhouse gas emissions across its entire value chain by 2045. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 55% by 2032 from a 2019 baseline and to eliminate Scope 1 emissions by 2040. Additionally, Biogen aims to reduce Scope 3 emissions by 90% by 2045, also from a 2019 base year. These targets align with the Science Based Targets initiative (SBTi) and reflect Biogen's commitment to sustainability within the pharmaceutical and biotechnology sector. The company is also working towards ensuring that 80% of its suppliers have science-based targets by 2025, further enhancing its sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 68,448,000 | 00,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 61,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 436,353,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biogen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
